Holen Sie sich die Stockscreener-App
40.97
0.00%
0.00
Handel nachbörslich:
40.99
0.02
+0.05%
Schlusskurs vom Vortag:
$40.97
Offen:
$40.95
24-Stunden-Volumen:
2.84M
Relative Volume:
0.57
Marktkapitalisierung:
$5.25B
Einnahmen:
$1.00B
Nettoeinkommen (Verlust:
$22.39M
KGV:
331.74
EPS:
0.1235
Netto-Cashflow:
$45.01M
1W Leistung:
-0.05%
1M Leistung:
+1.39%
6M Leistung:
+105.36%
1J Leistung:
+105.06%
1-Tages-Spanne:
$40.93
$40.98
1-Wochen-Bereich:
$40.93
$40.99
52-Wochen-Spanne:
$16.10
$41.00
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.97 | 5.25B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Eingeleitet | Roth Capital | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Executive Provisions - Minichart
Top 3 Health Care Stocks That May Collapse This Month - Benzinga
Apellis Updates Executive Separation Plan Amid Biogen Merger - TipRanks
Apellis (APLS) revises executive separation plan tied to Biogen merger - Stock Titan
MSN Money - MSN
Apellis Cell And Gene Update Puts Growth Story In Investor Focus - Sahm
Pictet Asset Management Holding SA Has $9.84 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
UBS Group AG Boosts Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases 49,642 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Jennison Associates LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis (NASDAQ: APLS) CMO reports bona fide gift of 900 shares - Stock Titan
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
M&T Bank Corp Has $1.38 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS stock soars 140% today – here’s everything to know about its massive $5.6B deal with Biogen - MSN
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Apellis earnings up next: Last report before Biogen takeover? By Investing.com - Investing.com Canada
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Apellis (APLS) Acquisition to Enhance Biogen's Growth Potential - GuruFocus
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Wednesday - MarketBeat
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Apellis Pharmaceuticals stock hits 52-week high at $40.96 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals stock hits 52-week high at $40.96 - Investing.com
Apellis surges on $5.6B buyout deal with Biogen - MSN
Apellis (NASDAQ: APLS) outlines 2025 executive pay, board and risk oversight - Stock Titan
Cwm LLC Sells 52,353 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on - MSN
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS): A Fitting GARP Opportunity - ChartMill
Why is Apellis Pharmaceuticals (APLS) down 17.3% since last earnings report? - MSN
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - MSN
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
Cantor Fitzgerald downgrades Apellis Pharmaceuticals (APLS) - MSN
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):